<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cagrilintide: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-cagrilintide</link>
    <atom:link href="https://greypeptides.com/changes/cagrilintide.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about Cagrilintide on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 18 Nov 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>New guide: What lab testing shows</title>
      <link>https://greypeptides.com/testing/#c-cagrilintide</link>
      <guid isPermaLink="false">greypeptides-changes-cagrilintide-guide-/testing/#c-cagrilintide</guid>
      <pubDate>Wed, 18 Nov 2026 12:00:00 +0000</pubDate>
      <category>New guide</category>
      <description>The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.</description>
    </item>
    <item>
      <title>News: Petrelintide's Phase 2 Paper Is Out: Weight Loss Levelled Off Above 5 mg. What Else EASD 2026 Showed</title>
      <link>https://greypeptides.com/news/easd-2026-petrelintide-peptide-data/</link>
      <guid isPermaLink="false">greypeptides-changes-cagrilintide-news-easd-2026-petrelintide-peptide-data</guid>
      <pubDate>Fri, 02 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Petrelintide's Phase 2 Paper Is Out: Weight Loss Levelled Off Above 5 mg. What Else EASD 2026 Showed</description>
    </item>
    <item>
      <title>News: CagriSema's Diabetes Trials Read Out: What REIMAGINE 1, 2 and 3 Found</title>
      <link>https://greypeptides.com/news/reimagine-cagrisema-type2-diabetes/</link>
      <guid isPermaLink="false">greypeptides-changes-cagrilintide-news-reimagine-cagrisema-type2-diabetes</guid>
      <pubDate>Wed, 30 Sep 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>CagriSema's Diabetes Trials Read Out: What REIMAGINE 1, 2 and 3 Found</description>
    </item>
    <item>
      <title>News: REDEFINE-1 Body Composition Data: How CagriSema Affects Muscle Mass</title>
      <link>https://greypeptides.com/news/cagrisema-redefine-1-body-composition-eco2026/</link>
      <guid isPermaLink="false">greypeptides-changes-cagrilintide-news-cagrisema-redefine-1-body-composition-eco2026</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>REDEFINE-1 Body Composition Data: How CagriSema Affects Muscle Mass</description>
    </item>
    <item>
      <title>Regulatory alert: US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.</title>
      <link>https://greypeptides.com/regulatory/alerts/#fda-wl-two-online-sellers-march</link>
      <guid isPermaLink="false">greypeptides-changes-cagrilintide-alert-fda-wl-two-online-sellers-march</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 +0000</pubDate>
      <category>Regulatory alert</category>
      <description>The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence.</description>
    </item>
  </channel>
</rss>
